Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems.

Grace C HerronDeborah DeCamilloXiaowen KongBrian HaymartScott KaatzStacy EllsworthMona A AliChristopher GiulianoJames B FroehlichGeoffery D Barnes

Published in: Thrombosis and haemostasis (2024)

This study demonstrates the benefit of DOAC prescribing oversight using a registry-based intervention to monitor for off-label dosing for the entirety of the time period a patient is prescribed DOAC, particularly for patients with AF, as off-label prescribing occurs frequently during the follow-up period.

Keyphrases

direct oral anticoagulants
atrial fibrillation
venous thromboembolism
primary care
randomized controlled trial
case report
adverse drug
emergency department